Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the …
K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer
K36 Therapeutics, Inc. (“K36”), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor …
